[e-drug] Pharma must be held more accountable to its human rights responsibilities

e-drug
1

E-DRUG: Pharma must be held more accountable to its human rights responsibilities
-------------------------------------

From the Public Library of Science

Pharma must be held more accountable to its human rights responsibilities
Freely available Paper at PLoS <http://cts.vresp.com/c/?PublicLibraryofScien/6da492ffa7/38ebd038c2/18a1f62725&gt;
http://www.plosmedicine.org/article/info%3Adoi2F10.13712Fjournal.pmed.1000344

In this week�s PLoS Medicine (2010; 7(9), September issue), the Editors argue that drug companies should be held much more accountable for their human rights responsibilities to make medicines available and accessible to those in need. Despite decades of advocacy on the part of the access to medicines movement, and human rights guidelines developed in 2008 for pharmaceutical companies that make clear that their responsibilities go beyond stakeholder value to encompass human rights, there is inadequate accountability, say the Editors. �At the same time that the 825 billion dollar global pharmaceutical industry operates as society�s chief developer and purveyor of life-saving medicine, two billion people around the world lack access to essential medicines. Such a persistent perversity demands more outrage,� argue the Editors.

The editorial accompanies a series of viewpoints in a commissioned PLoS Medicine Debate on the topic of whether drug companies are living up to their human rights responsibilities. In the Debate, three unique perspectives are offered: Sofia Gruskin and Zyde Raad from the Harvard School of Public Health say more assessment is needed of human rights responsibilities; Geralyn Ritter, Vice President of Global Public Policy and Corporate Responsibility at Merck & Co. argues that multiple stakeholders could do more to help States deliver the right to health; and Paul Hunt and Rajat Khosla introduce Mr. Hunt�s work as the UN Special Rapporteur on the right to the highest attainable standard of health (2002?2008), regarding the human rights reesponsibilities of pharmaceutical companies and access to medicines.

�The importance and significance of accountability in this area cannot be overstated,� say the Editors. �Beyond an add-on or peripheral activity, the acknowledgement and promotion of human rights must become a regular, integrated aspect of the work of pharmaceutical companies. Better yet would also be an external, international body charged explicitly with monitoring the policies and practices of pharmaceutical companies and reporting publicly on the discharge of their right-to-health responsibilities.�

* * * * * * * * * * * * * * * * * * *
The PLoS Medicine Debate: Moving Toward Assessment by Sofia Gruskin, Zyde Raad

Funding: No specific funding was received for this piece.

Competing Interests: SG is director of and ZR is program manager at the Program on International Health and Human Rights (PIHHR) at Harvard School of Public Health. PIHHR has received funding from the Merck Company Foundation for a several-year project exploring the roles and responsibilities of the pharmaceutical industry as well as other state and non-state actors with regard to alleviating disease burdens worldwide.

Citation: Gruskin S, Raad Z (2010) Are Drug Companies Living Up to Their Human Rights Responsibilities? Moving Toward Assessment. PLoS Med 7(9):e1000310. doi:10.1371/journal.pmed.1000310
<http://cts.vresp.com/c/?PublicLibraryofScien/6da492ffa7/38ebd038c2/cda60dab6e&gt;
http://www.plosmedicine.org/article/info%3Adoi%2F10.13712Fjournal.pmed.1000310

* * * * * * * * * * * * * * * * * * * * *
The PLoS Medicine Debate: The Perspective of the Former United Nations Special Rapporteur (2002-2008) by Paul Hunt and Rajat Khosla

Competing Interests: The views expressed in this article are those of the authors and cannot be attributed to any organization

Citation: Hunt P, Khosla R (2010) Are Drug Companies Living Up to Their Human Rights Responsibilities? The Perspective of the Former United Nations Special Rapporteur (2002-2008). PLoS Med 7(9): e1000330. doi:10.1371/journal.pmed.1000330
<http://cts.vresp.com/c/?PublicLibraryofScien/6da492ffa7/38ebd038c2/a25f43629b&gt;
http://www.plosmedicine.org/article/info%3Adoi%2F10.13712Fjournal.pmed.1000330

* * * * * * * * * * * * * * * * * * *
The PLoS Medicine Debate: The Merck Perspective by Geralyn Ritter

Competing Interests: Geralyn Ritter is Vice President, Global Public Policy and Corporate Responsibility at Merck & Co. and holds equity in Merck.

Citation: Ritter GS (2010) Are Drug Companies Living Up to Their Human Rights

Responsibilities? The Merck Perspective. PLoS Med 7(9): e1000343. doi:10.1371/journal.pmed.1000343
<http://cts.vresp.com/c/?PublicLibraryofScien/6da492ffa7/38ebd038c2/886b4d3279&gt;
http://www.plosmedicine.org/article/info%3Adoi%2F10.13712Fjournal.pmed.1000343